Prospective randomized trial of oxytocin administration for active management of the third stage of labor
International Journal of Gynecology and Obstetrics, cilt.127, sa.2, ss.175-179, 2014 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 127 Sayı: 2
- Basım Tarihi: 2014
- Doi Numarası: 10.1016/j.ijgo.2014.05.022
- Dergi Adı: International Journal of Gynecology and Obstetrics
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.175-179
- Anahtar Kelimeler: Active management of third stage of labor, Labor augmentation, Oxytocin, Postpartum hemorrhage
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: To determine the most efficient route and timing of oxytocin administration for active management of the third stage of labor. Methods: A prospective randomized study was done at one center in Ankara, Turkey, between January and October 2010.Women with a singleton pregnancy (>37 weeks) who had a live vaginal birth were randomly allocated to four groups: iv-A (intravenous oxytocin after delivery of the fetus), iv-B (when anterior shoulder seen), im-A (intramuscular oxytocin after delivery), and im-B (when anterior shoulder seen). Postpartum blood loss within the first hour, hemoglobin, hematocrit, and duration of the third stage were compared. Results: A total of 600 eligiblewomen were recruited; 150were assigned to each group. Postpartumblood loss, prepartum and postpartum hemoglobin and hematocrit, and need for additional uterotonics were similar among groups (P > 0.05). The duration of the third stage of labor and changes in hemoglobin and hematocrit were significantly reduced in group iv-B (P < 0.05). Among women not exposed to oxytocin before delivery, postpartum blood losswas significantly lower in group iv-B (P= 0.019). Labor augmentationwas related to significantly increased postpartumblood loss in all groups except iv-A. Conclusion: Although postpartum blood loss was similar in all groups, early intravenous administration seemed to have beneficial effects. ClinicalTrials.gov: NCT01954186.